Lars is one of TranScrip’s key experts in respiratory, allergic and immunological diseases.
He has more than 40 years’ experience of clinical work in the disease areas, and more than 20 years’ pharma experience covering all stages of global drug development including biopharmaceuticals, MABs and antisense oligonucleotides, systemic as well as inhaled. In addition, he has extensive experience in licensing and evaluation/due diligence of pharma and biotech projects.
Lars became MD at the University of Umeå, Sweden, in 1977 and holds board certificates in Internal Medicine, Pulmonary Medicine and Allergy. He is Associated Professor in Pulmonary Medicine at the University of Umeå. After several years in full time clinical work in internal medicine and respiratory medicine, he joined Astra (later AstraZeneca) in 1995 as medical adviser, and then advanced to head Medical Department at Astra Draco in 1997. In 1999 he moved to Pharmacia Diagnostics AB as VP Medical and Regulatory Affairs and later held positions as VP and CMO at a number of biotech companies, including Biolipox AB and Resistentia, before moving on to his role as Clinical Research Head Cough, Cold and Allergy, at Novartis Consumer health. Most recently he was Executive Medical Director Licensing for Respiratory and Inflammation therapeutic area in AstraZeneca.
During his years in industry, Lars has worked in small start-up biotech companies as well as large pharma companies and has been involved in all stages of drug development of biopharmaceuticals, large molecules and oligonucleotides, including inhaled delivery of large molecules. He has interacted with regulatory authorities in Europe as well as USA and Japan on several occasions, and worked closely with commercial colleagues to find the optimal positioning for novel treatments. He has also organised and participated in numerous advisory boards and KOL meetings, and organised and spoken at company arranged symposia.
Whilst working as CMO in biotech companies, and more recently as a board member, Lars has actively participated in fund raising and IPO processes. As Executive Medical Director Licensing he has also gained a lot of experience in evaluating external projects and closing licensing deals in several therapeutic areas.
Since joining Transcrip in 2013 he has worked in several small and mid-sized companies designing and executing development programs in respiratory and allergic diseases. The work has included small as well as large molecules and systemic as well as inhaled routes. He has also organised and taken part in authority meetings and KOL ad boards..
Key areas of expertise
1. Drug development
2. Due diligence
3. Inhaled therapeutics